Active Protocols at the Clinic
Our team has rigorous guidelines in place to protect the well-being and safety of clinical trial participants, who are, of course, always fully aware of their participation. This research is carried out in collaboration with Greek and international academic and research institutions and usually results in publication of research papers in peer review journals.
MSD- MK 3475 B2: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent
ZEAL: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancerk.
EXELIXIS: A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov Identifier: NCT0444611
KEYNOTE B49: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor- Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer.
EORTC PROTOCOL 1419-BTG:
Molecular genetic, host-derived and clinical determinants of long-term
survival in glioblastoma with the following goals:
- Identification of clinical parameters and patient characteristics / hostrelated factors in long-term survivors (Focus 1)
- Identification of molecular tumor characteristics in long-term survivors
- Assessment of therapy-related parameters, including neuro-toxicity
- Immunological studies (Focus 4)
A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator’s Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation